Connection

John Wrangle to Immunoconjugates

Back to Details
This is a "connection" page, showing publications John Wrangle has written about Immunoconjugates.
John Wrangle
Connection Strength
0.188
Immunoconjugates
  1. A Phase 1-2 Study of Rovalpituzumab Tesirine in Combination With Nivolumab Plus or Minus Ipilimumab in Patients With Previously Treated Extensive-Stage SCLC. J Thorac Oncol. 2021 09; 16(9):1559-1569.
    View in: PubMed
    Score: 0.188
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.